Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA4 | P22748 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 8/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16207212 | 0.93 | ALOX5 (0.40) | ALOX5ALDH1A1SMN1; SMN2CA1CA2 | |
| SCHEMBL14546126 | 0.90 | ALOX5 (0.48) | ALOX5ALDH1A1SMN1; SMN2LMNAHSD17B10 | |
| SCHEMBL15960434 | 0.85 | ALOX5 (0.46) | ALOX5ALDH1A1SMN1; SMN2CA1CA2 | |
| SCHEMBL24599953 | 0.81 | ALOX5 (0.60) | ALOX5ALDH1A1SMN1; SMN2LMNAHSD17B10 | |
| SCHEMBL15959624 | 0.81 | ALOX5 (0.60) | ALOX5ALDH1A1SMN1; SMN2LMNAHSD17B10 | |
| SCHEMBL13060191 | 0.81 | ALOX5 (0.60) | ALOX5ALDH1A1SMN1; SMN2LMNAHSD17B10 | |
| SCHEMBL14873017 | 0.81 | CA1 (0.56) | ALDH1A1SMN1; SMN2CA1CA2CA4 | |
| SCHEMBL12036601 | 0.81 | ALOX5 (0.60) | ALOX5ALDH1A1SMN1; SMN2LMNAHSD17B10 | |
| SCHEMBL11913449 | 0.81 | ALOX5 (0.60) | ALOX5ALDH1A1SMN1; SMN2LMNAHSD17B10 | |
| SCHEMBL16411466 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9163032-B2 | Esters of DCPLA and methods of treatment using the same | Blanchette Rockefeller Neurosciences Insitute (US) | 2015-10-20 | — | — | US | disclosed |
| US-20140323456-A1 | ESTERS OF DCPLA AND METHODS OF TREATMENT USING THE SAME | COGNITIVE RESEARCH ENTERPRISES, INC. | 2014-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140323456-A1 | ESTERS OF DCPLA AND METHODS OF TREATMENT USING THE SAME | LIPA, PCCA, PNLIP | ALOX5 130/4885ALDH1A1 780/4885SMN1; SMN2 3446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.